NCT05659602View on ClinicalTrials.gov

A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients

NACompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

July 9, 2022

Primary Completion Date

January 3, 2023

Study Completion Date

January 3, 2023

Conditions
Coronavirus Disease 2019(COVID-19)
Interventions
BIOLOGICAL

HH-120 Nasal Spray

HH-120 Nasal Spray 8-10 times per day for 6 consecutive days

Trial Locations (1)

Unknown

Beijing Ditan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Ditan Hospital

OTHER